Harvard Bioscience Inc (HBIO)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $42.94M
Last updated: Nov 17, 2026 at 11:03 AM ET
Harvard Bioscience Inc (HBIO) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Harvard Bioscience reported EPS of -$0.16, above the -$0.65 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
HBIO's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
HBIO Earnings Call
The latest HBIO earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, HBIO beat 13, missed 19 and matched 7. Revenue for the quarter ended Sep 30, 2026 was $22.20M, up 7.8% from $20.59M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.16 | -$0.65 | N/A | +75.38% | Beat | N/A | 2 | 1 up, 0 down | Nov 10, 2026 | $22.20M |
| Jun 30, 2026 | -$0.22 | -$0.21 | -$0.35 - -$0.07 | -4.76% | Miss | N/A | 2 | 0 up, 1 down | Aug 11, 2026 | $22.73M |
| Mar 31, 2026 | -$0.77 | -$0.95 | N/A | +18.95% | Beat | N/A | 1 | 0 up, 1 down | May 12, 2026 | $20.75M |
| Dec 31, 2025 | -$0.64 | $0.04 | $0.03 - $0.04 | N/A | N/A | -1695.8% | 2 | 0 up, 2 down | Mar 12, 2026 | $23.73M |
| Sep 30, 2025 | -$0.03 | $0.05 | $0.00 - $0.10 | -160.00% | Miss | N/A | 2 | 1 up, 0 down | Nov 6, 2025 | $20.59M |
| Jun 30, 2025 | -$0.10 | -$0.25 | -$0.30 - -$0.20 | +60.00% | Beat | N/A | 2 | 0 up, 2 down | Aug 11, 2025 | $20.45M |
| Mar 31, 2025 | -$0.10 | -$0.40 | -$0.60 - -$0.20 | +75.00% | Beat | -150.0% | 2 | 0 up, 2 down | May 12, 2025 | $21.77M |
| Dec 31, 2024 | $0.04 | $0.05 | $0.04 - $0.06 | -20.00% | Miss | 0.0% | 2 | 1 up, 1 down | Mar 12, 2025 | $24.56M |
| Sep 30, 2024 | -$0.20 | $0.15 | $0.00 - $0.50 | -233.33% | Miss | -300.0% | 3 | 0 up, 0 down | Nov 7, 2024 | $21.97M |
| Jun 30, 2024 | -$0.07 | $0.50 | $0.30 - $0.70 | -113.46% | Miss | -116.8% | 2 | 0 up, 0 down | Aug 8, 2024 | $23.10M |
| Mar 31, 2024 | $0.20 | $0.25 | $0.20 - $0.30 | -20.00% | Miss | -66.7% | 3 | 0 up, 0 down | May 7, 2024 | $24.51M |
| Dec 31, 2023 | $0.04 | $0.05 | $0.05 - $0.05 | -20.00% | Miss | 0.0% | 3 | 0 up, 0 down | Mar 7, 2024 | $28.15M |
| Sep 30, 2023 | $0.10 | $0.40 | $0.40 - $0.40 | -75.00% | Miss | N/A | 3 | 0 up, 0 down | Nov 7, 2023 | $25.36M |
| Jun 30, 2023 | $0.40 | $0.55 | $0.50 - $0.80 | -27.27% | Miss | -20.0% | 3 | 0 up, 0 down | Aug 8, 2023 | $28.76M |
| Mar 31, 2023 | $0.60 | $0.45 | $0.40 - $0.60 | +33.33% | Beat | +50.0% | 3 | 0 up, 0 down | Apr 25, 2023 | $29.98M |
| Dec 31, 2022 | $0.04 | $0.03 | $0.00 - $0.09 | +33.33% | Beat | -50.0% | 3 | 0 up, 0 down | Mar 9, 2023 | $28.43M |
| Sep 30, 2022 | -$0.10 | $0.55 | $0.50 - $0.90 | -118.18% | Miss | -116.7% | 3 | 1 up, 0 down | Nov 8, 2022 | $26.92M |
| Jun 30, 2022 | $0.50 | $0.55 | $0.30 - $0.80 | -9.09% | Miss | -16.7% | 3 | 0 up, 0 down | Aug 3, 2022 | $29.21M |
| Mar 31, 2022 | $0.40 | $0.55 | $0.50 - $0.60 | -27.27% | Miss | -20.0% | 3 | 0 up, 0 down | May 4, 2022 | $28.78M |
| Dec 31, 2021 | $0.08 | $0.10 | $0.08 - $0.13 | -20.00% | Miss | 0.0% | 3 | 0 up, 0 down | Mar 8, 2022 | $33.05M |
| Sep 30, 2021 | $0.60 | $0.60 | $0.60 - $0.60 | 0.00% | In line | +50.0% | 3 | N/A | Nov 3, 2021 | $29.66M |
| Jun 30, 2021 | $0.60 | $0.65 | $0.50 - $0.80 | -7.69% | Miss | +20.0% | 3 | N/A | Aug 5, 2021 | $29.20M |
| Mar 31, 2021 | $0.50 | $0.25 | $0.20 - $0.50 | +100.00% | Beat | N/A | 3 | N/A | May 6, 2021 | $26.99M |
| Dec 31, 2020 | $0.08 | $0.07 | $0.06 - $0.07 | +14.29% | Beat | 0.0% | 2 | N/A | Mar 10, 2021 | $30.98M |
| Sep 30, 2020 | $0.40 | $0.20 | $0.20 - $0.50 | +100.00% | Beat | 0.0% | 2 | N/A | Nov 5, 2020 | $24.04M |
| Jun 30, 2020 | $0.50 | -$0.10 | -$0.50 - -$0.10 | +600.00% | Beat | +25.0% | 2 | N/A | Aug 5, 2020 | $23.31M |
| Mar 31, 2020 | -$0.10 | $0.30 | $0.20 - $0.40 | -133.33% | Miss | -150.0% | 3 | N/A | May 5, 2020 | $23.77M |
| Dec 31, 2019 | $0.08 | $0.09 | $0.08 - $0.10 | -11.11% | Miss | +14.3% | 3 | N/A | Feb 26, 2020 | $30.97M |
| Sep 30, 2019 | $0.40 | $0.50 | $0.40 - $0.60 | -20.00% | Miss | 0.0% | 3 | N/A | Nov 5, 2019 | $27.42M |
| Jun 30, 2019 | $0.40 | $0.40 | $0.40 - $0.40 | 0.00% | In line | -42.9% | 3 | N/A | Jul 25, 2019 | $29.58M |
| Mar 31, 2019 | $0.20 | $0.35 | $0.30 - $0.40 | -42.86% | Miss | -33.3% | 3 | N/A | May 2, 2019 | $28.20M |
| Dec 31, 2018 | $0.07 | $0.07 | $0.07 - $0.07 | 0.00% | In line | +40.0% | 3 | N/A | Feb 28, 2019 | $33.86M |
| Sep 30, 2018 | $0.40 | $0.40 | $0.40 - $0.40 | 0.00% | In line | +33.3% | 3 | N/A | Oct 25, 2018 | $28.64M |
| Jun 30, 2018 | $0.70 | $0.53 | $0.50 - $0.60 | +32.08% | Beat | +133.3% | 3 | N/A | Jul 26, 2018 | $31.52M |
| Mar 31, 2018 | $0.30 | $0.27 | $0.20 - $0.30 | +11.11% | Beat | +50.0% | 3 | N/A | May 2, 2018 | $26.76M |
| Dec 31, 2017 | $0.05 | $0.05 | $0.05 - $0.06 | 0.00% | In line | +25.0% | 3 | N/A | Mar 1, 2018 | $21.65M |
| Sep 30, 2017 | $0.30 | $0.33 | N/A | -9.09% | Miss | 0.0% | N/A | N/A | Oct 26, 2017 | $18.72M |
| Jun 30, 2017 | $0.30 | $0.30 | N/A | 0.00% | In line | 0.0% | N/A | N/A | Jul 27, 2017 | $18.96M |
| Mar 31, 2017 | $0.20 | $0.13 | N/A | +53.85% | Beat | -60.0% | N/A | N/A | Apr 27, 2017 | $18.09M |
| Dec 31, 2016 | $0.04 | $0.04 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 9, 2017 | $26.41M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.87, after -$0.03 the year before. It was $1.14 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.87 | N/A |
| Dec 31, 2024 | -$0.03 | -102.4% |
| Dec 31, 2023 | $1.14 | +35.7% |
| Dec 31, 2022 | $0.84 | -52.8% |
| Dec 31, 2021 | $1.78 | +102.3% |
| Dec 31, 2020 | $0.88 | -18.5% |
| Dec 31, 2019 | $1.08 | -26.5% |
| Dec 31, 2018 | $1.47 | +72.9% |
| Dec 31, 2017 | $0.85 | -25.4% |
| Dec 31, 2016 | $1.14 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,600 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,603 | 7 | |
| 2026Q2 | Jun 30, 2026 | 2,876 | 6 | |
| 2026Q1 | Mar 31, 2026 | 2,755 | 6 | |
| 2025Q4 | Dec 31, 2025 | 3,126 | 6 | |
| 2025Q3 | Sep 30, 2025 | 2,678 | 6 | |
| 2025Q2 | Jun 30, 2025 | 2,683 | 6 | |
| 2025Q1 | Mar 31, 2025 | 4,144 | 6 | |
| 2024Q4 | Dec 31, 2024 | 4,326 | 6 |
2026Q3 Earnings Call
Opening remarks
Taylor Krafchik Senior Vice President Thank you, operator. Good morning, everyone. Thank you for joining the Harvard Bioscience Third Quarter 2026 Earnings Conference Call. Leading the call today will be John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer. In conjunction with today's recorded call, we have provided a presentation that will be referenced during our remarks, which is posted to the Investor Relations section of our website at investor.harvardbioscience.com. Please note that statements made in today's discussion that are not historical facts, including statements on management's expectations of future events or future financial performance, are forward-looking statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current views of Harvard Bioscience's management, and Harvard Bioscience assumes no obligation to update or revise any forward-looking statements. Actual results may differ materially from those expressed or implied. Please refer to today's press release, the Harvard Bioscience Form 10-Q, and other filings with the Securities and Exchange Commission for additional disclosures on forward-looking statements and the risks, uncertainties, and contingencies associated therewith. During the call, management will also reference certain non-GAAP financial measures, which can be useful in evaluating the company's operations related to our financial condition and results. These non-GAAP measures are intended to supplement GAAP financial information and should not be considered a substitute. Reconciliations of GAAP to non-GAAP measures are provided in today's earnings press release. I will now turn the call over to John. John, please go ahead.
John Duke President and Chief Executive Officer Thank you, Taylor, and good morning, everyone. In the third quarter, we delivered another solid quarter of top-line performance with 8% revenue growth, driven by strength across key preclinical platforms and double-digit momentum in products for organoids, fluidics, and our new product innovation. To give a high-level summary before Mark dives into the detailed financials, our results were in line with our expectations. Revenue came in at $22.2 million, representing 8% growth year over year, marking our second consecutive quarter of strong revenue growth. Adjusted gross margin was 57.1%, including higher volume in CMT products, increased sales through distribution partners, and growth in China, which carried lower gross margins. Adjusted EBITDA was $1.8 million, reflecting the same factors that impacted gross margin. Strong sales to CRO customers were driven by sales of our telemetry, respiratory, and inhalation products. CRO sales are up meaningfully year to date, reflecting healthy demand as biopharma customers increasingly rely on external research partners. We also saw continued growth from our biopharma customers. Across the broader drug development landscape, industry tailwinds remain supportive of future growth.
Frequently Asked Questions About HBIO
Did HBIO beat earnings estimates last quarter?
Yes. Harvard Bioscience reported EPS of -$0.16 for the quarter ended Sep 30, 2026, above the -$0.65 estimate, a 75.38% surprise.
What EPS do analysts expect from HBIO next quarter?
The consensus EPS estimate for Harvard Bioscience for the quarter ending Dec 31, 2026 is $0.19 from 4 analysts, with estimates from $0.08 to $0.32.
How often does HBIO beat earnings estimates?
Harvard Bioscience beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of -23.60%.
HBIO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts